Chimeron Bio develops agents for personalized cancer gene therapy.
Chimeron Bio has raised $12.8M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in March 2025.
Chimeron Bio's investors include Dreavent Capital.
Chimeron Bio is headquartered in Philadelphia, United States.
Chimeron Bio develops agents for personalized cancer gene therapy.
Chimeron Bio is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Chimeron Bio — Funding & Investors." VCBacked, March 14, 2025, https://www.vcbacked.co/company/chimeron-bio. Accessed August 17, 2026.
VCBacked. (2025). Chimeron Bio — Funding & Investors. Retrieved August 17, 2026, from https://www.vcbacked.co/company/chimeron-bio
{{cite web |title=Chimeron Bio — Funding & Investors |url=https://www.vcbacked.co/company/chimeron-bio |website=VCBacked |access-date=August 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated